Skip to main content
Premium Trial:

Request an Annual Quote

Guardant Health Completes Purchase of Guardant Health AMEA Joint Venture

NEW YORK – Guardant Health said Monday that it has completed its previously announced purchase of Guardant Health AMEA, a joint venture between the US liquid biopsy firm and global investment firm SoftBank, which launched initially in 2018.

Under the terms of the parties’ joint venture agreement, Guardant Health paid approximately $177.8 million to acquire the remaining shares held by SoftBank and its affiliates. The company now has full control over operations throughout the Asia, Middle East, and Africa region.

"By acquiring the remaining shares of Guardant Health AMEA, we can focus on creating a unified and centralized global organization that delivers on our promise to help conquer cancer and improve patient outcomes," Guardant Chairman and co-CEO Helmy Eltoukhy said in a statement. "We believe our blood-based tests can play a significant role in helping address the growing incidence of cancer in the region, and we look forward to continuing to support patients facing cancer diagnoses as we expand our operations in these markets."

Guardant Health AMEA operations currently support 41 countries across the region. Near term, Guardant said it will prioritize bringing blood-based testing to healthcare providers and to patients with advanced cancer in Japan, where the Japanese Ministry of Health, Labor, and Welfare recently approved the firm's Guardant360 CDx test.


The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.